Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy

Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy

Aim: to evaluate the pharmacoeconomic efficacy of the application of the atesolizumab (PD-L1 inhibitor) preparation compared with other control point inhibitors (PD-1 inhibitors) in patients with advanced non-small cell lung cancer (NSCLC) after chemothe rapy.Materials and methods. Study design incl...

Full description

Bibliographic Details
Main Authors:	S. K. Zyryanov, I. N. Diyakov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2020-04-01
Series:	Фармакоэкономика
Subjects:	common non-small cell lung cancer second line of therapy third line of therapy control point inhibitors pd-1/pd-l1 inhibitors atesolizumab pembrolizumab nivolumab cost minimization budget impact
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/338

Similar Items

Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy
by: S. K. Zyryanov, et al.
Published: (2023-11-01)

Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies
by: Chenxi Sun, et al.
Published: (2023-12-01)

The efficacy of PD‐1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study
by: Ryosuke Sato, et al.
Published: (2022-12-01)

The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
by: Takashi Kurosaki, et al.
Published: (2023-12-01)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024-02-01)

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
by: Yang Wang, et al.
Published: (2023-02-01)

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma
by: Yuta Hoshi, et al.
Published: (2024-05-01)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
by: Miaomiao Gou, et al.
Published: (2023-05-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti‐pd‐1/pd-l1 therapy
by: Eda Alp, et al.
Published: (2024-12-01)

Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
by: Daniella Kuzmanovszki, et al.
Published: (2022-07-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
by: Shubin Chen, et al.
Published: (2022-12-01)

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
by: Sung Hee Lim, et al.
Published: (2024-02-01)

Which Is More Suitable for First‐Line Treatment of Extensive‐Stage Small Cell Lung Cancer, PD‐L1 Inhibitors Versus PD‐1 Inhibitors? A Systematic Review and Network Meta‐Analysis
by: Wenjing Liu, et al.
Published: (2024-07-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors
by: Bei W, et al.
Published: (2024-07-01)

PD-1 inhibitors in advanced esophageal squamous cell carcinoma: a survival analysis of reconstructed patient-level data
by: Chunyan Yan, et al.
Published: (2024-07-01)

Extra-cranial radiotherapy in anti-PD-1-treated melanoma patients: A systematic review
by: Philippe Saiag, et al.
Published: (2024-12-01)

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan
by: Takamichi Ito, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
by: Shixian Liu, et al.
Published: (2023-03-01)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
by: Enikő Sebestyén, et al.
Published: (2023-10-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Severe lichenoid eruption due to concomitant medications following nivolumab administration
by: Risa Kakuta, et al.
Published: (2023-09-01)

Primary pulmonary histiocytic sarcoma with high PD‐L1 expression benefited from immunotherapy: A case report and bioinformatic analysis
by: Yuanjie Lin, et al.
Published: (2024-03-01)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
by: Paul Lesueur, et al.
Published: (2018-11-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
by: Yihang Qi, et al.
Published: (2022-09-01)

The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
by: Shubin Chen, et al.
Published: (2023-08-01)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
by: Joanna Bialek, et al.
Published: (2022-12-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

NEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
by: A. M. Mudunov, et al.
Published: (2017-06-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis
by: Yanhao Liu, et al.
Published: (2024-03-01)

Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma
by: Pandiselvi Ravi, et al.
Published: (2024-12-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis
by: Ze Mi, et al.
Published: (2022-12-01)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
by: Melissa Bersanelli, et al.
Published: (2022-05-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
by: Jie Yang, et al.
Published: (2024-08-01)

A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)
by: Charbel Elias, et al.
Published: (2022-12-01)